Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

Lancet Oncology

Volumn 8, Issue 7, 2007, Pages 595-602

  Grosso, Federica ^a   Jones, Robin L ^b   Demetri, George D ^c   Judson, Ian R ^b   Blay, Jean Yves ^d   Le Cesne, Axel ^e   Sanfilippo, Roberta ^a   Casieri, Paola ^a   Collini, Paola ^a   Dileo, Palma ^a   Spreafico, Carlo ^a   Stacchiotti, Silvia ^a   Tamborini, Elena ^a   Tercero, Juan Carlos ^f   Jimeno, Josè ^f   D'Incalci, Maurizio ^g   Gronchi, Alessandro ^a   Fletcher, Jonathan A ^h   Pilotti, Silvana ^a   Casali, Paolo G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f PHARMAMAR S A   (Spain)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; IFOSFAMIDE; TRABECTEDIN;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIPOSARCOMA, MYXOID; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; RETROSPECTIVE STUDIES; TETRAHYDROISOQUINOLINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34347214071     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70175-4     Document Type: Article

References (31)

1. In: Fletcher C., Unni K., and Mertens F. (Eds). Pathology and genetics of tumours of soft tissue and bone. World Health Organization classification of tumours volume 5 (2002), IARC Press, Lyon, France
2. Brennan M., Alektiar K., and Maki R. Soft tissue sarcoma. In: DeVita Jr. V., Hellman S., and Rosenberg S. (Eds). Cancer: principles and practice of oncology. 6th edn. (2001), Lippincott Williams & Wilkins, Philadelphia 1841-1980
3. Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13 (1995) 1537-1545
4. Izbicka E., Lawrence R., Raymond E., et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9 (1998) 981-987
5. Taamma A., Misset J., Riofrio M., et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous inFusion in patients with solid tumors. J Clin Oncol 19 (2001) 1256-1265
6. Sessa C., De Braud F., Perotti A., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23 (2005) 1867-1874
7. Yovine A., Riofrio M., Blay J., et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22 (2004) 890-899
8. Garcia-Carbonero R., Supko J., Manola J., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22 (2004) 1480-1490
9. Le Cesne A., Blay J., Judson I., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23 (2005) 576-584
10. Garcia-Carbonero R., Supko J., et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23 (2005) 5484-5492
11. Orvieto E., Furlanetto A., Laurino L., and Dei Tos A. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol 18 (2001) 267-273
12. Panagopoulos I., Mertens F., Isaksson M., and Mandahl N. A novel FUS/CHOP chimera in myxoid liposarcoma. Biochem Biophys Res Commun 279 (2000) 838-845
13. Antonescu C., Tschernyavsky S., Decuseara R., Leung D., Woodruff J., and Brennan M. Prognostic impact of p53 status, TLS-CHOP Fusion transcript structure, and histologic grade in myxoid liposarcoma. Clin Cancer Res 6 (2000) 2788-2793
14. Spillane A., Fisher C., and Thomas J. Myxoid liposarcoma-the frequency and the natural history of nonpulmonary soft tissue metastases. Ann Surg Oncol 6 (1999) 389-394
15. Fiore M., Grosso F., Lo Vullo S., et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2007) (in press)
16. Singer S., Demetri G., Baldini E., and Fletcher C. Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 1 (2000) 75-85
17. Keohan M., and Taub R. Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities. Semin Oncol 24 (1997) 572-579
18. Van Glabbeke M., van Oosterom A., Oosterhuis J., et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17 (1999) 150-157
19. Jones R., Fisher C., Al-Muderis O., and Judson I. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41 (2005) 2853-2860
20. Patel S., Burgess M., Plager C., Papadopoulos N., Linke K., and Benjamin R. Myxoid liposarcoma. Experience with chemotherapy. Cancer 74 (1994) 1265-1269
21. Grosso F., Dileo P., Sanfilippo R., et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 42 (2006) 1484-1490
22. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
23. Kanoe H., Nakayama T., Hosaka T., et al. Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation. Oncogene 18 (1999) 721-729
24. Delaloge S., Yovine A., Taamma A., et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 19 (2001) 1248-1255
25. Demetri G., Fletcher C., Mueller E., et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96 (1999) 3951-3956
26. Casali P., Bertulli R., Fumagalli E., Coco P., Grosso F., and Stacchiotti S. Some lessons learned from Imatinib mesylate clinical development in gastrointestinal stromal tumors. J Chemother 16 (2004) 55-58
27. Demetri G., van Oosterom A., Garrett C., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006) 1329-1338
28. Casali P., Messina A., Stacchiotti S., et al. Imatinib mesylate in chordoma. Cancer 101 (2004) 2086-2097
29. Choi H., Charnsangavej C., de Castro Faria S., et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR 183 (2004) 1619-1628
30. Friedman D., Hu Z., Kolb E., Gorfajn B., and Scotto K. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 62 (2002) 3377-3381
31. Le Cesne A., Misset J., Demetri G., et al. Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24-h infusion schedule. Proc ECCO 11. Eur J Cancer 37 (2001) 34